The European Society for Medical Oncology (ESMO) is pleased to announce the publication of the latest version of the scale that measures the clinical benefit of cancer treatments, the ESMO-MCBS (ESMO-Magnitude of Clinical Benefit Scale).

Venous thromboembolism (VTE) is a life-threatening complication in children with serious underlying conditions such as heart defects or cancer. Treatment or prevention of thrombosis poses an additional challenge in everyday clinical practice. A therapy using the active ingredient rivaroxaban specifically tailored to children was successfully tested for the first time in 2020. Now, long-term data confirm the benefits of this drug treatment even for extended use. The study was conducted by an international research team led by MedUni Vienna and has been published in the journal The Lancet Haematology.

Penn Medicine researchers will present data on the latest advances in cancer science and medicine at the 2025 ASCO Annual Meeting. 

Researchers from The University of Texas MD Anderson Cancer Center will present research at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These oral presentations address multiple tumor types and highlight key studies in immunotherapy, targeted therapy, and treatment strategies for aggressive and rare cancers.

Moffitt Cancer Center will play a key role at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place May 30 to June 3 in Chicago. Physician-scientists and researchers from Moffitt are contributing to more than 30 oral, rapid-oral and poster presentations, offering new data and perspectives that could help shape the future of cancer care.

Scientists aiming to advance cancer diagnostics have developed a machine learning tool that is able to identify metabolism-related molecular profile differences between patients with colorectal cancer and healthy people.